Clinical Research Directory

Inclusion Criteria: 1. Age≥ 18 years old, gender is not limited; 2. Patients with hematologic malignancies such as leukemia and lymphoma who have undergone chemotherapy or hematopoietic stem cell transplantation; 3. Peripheral blood absolute neutrophil count (ANC) \< 0.5×109/L, or expected ANC \< 0.5×109/L after 48 h; 4. Within 48 hours before the screening, at least 2 oral temperature measurements (with an interval of more than 30 minutes) ≥ 38.3°C (axillary temperature≥38.0°C), or ≥ 38°C (axillary temperature≥37.7°C) for more than 1h; 5. Received broad-spectrum antimicrobial therapy for at least 96 hours before screening but still had recurrent or persistent fever and suspected fungal infection; 6. The patient or his/her legal representative signs the informed consent form. Exclusion Criteria: 1. Those who are allergic to amphotericin class B drugs or any component of the cholesterol-sulfate complex; 2. Patients with clinical suspicion of invasive fungal disease who have received antifungal therapy; 3. Patients with clinically diagnosed or confirmed invasive fungal disease (IFD) during the screening period; 4. Patients with abnormal liver function, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal (ULN), or ALT or AST \> 3 times ULN and total bilirubin \> 1.5 times ULN; 5. Patients with reduced renal function, who need or are currently undergoing hemodialysis or peritoneal dialysis; 6. Clinically significant hypokalemia (defined as serum potassium \< 3.2 mmol/L, or blood potassium lower than the lower limit of normal while receiving digitalis therapy), and hypokalemia cannot be corrected before starting trial treatment; 7. Expected survival time\< 3 months; 8. Pregnant women, lactating women, or women of childbearing age who have not taken contraceptive measures and are planning to become pregnant; 9. Other investigators believe that it is not appropriate to participate in clinical trials.